Mark M, Froesch P, Gysel K, Rothschild SI, et al. First-line durvalumab in patients with PD-L1 positive, advanced non-small cell lung cancer (NSCLC) with a performance status of 2 (PS2). Primary analysis of the multicenter, single-arm phase II trial SAKK 19/17. Eur J Cancer 2024;200:113600.
PMID: 38330766